Stockreport

NeuroMetrix Reports that Quell® Technology is to be Evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Randomized Controlled Trial

NeuroMetrix, Inc.  (NURO) 
Last neurometrix, inc. earnings: 4/20 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.neurometrix.com/investor-relations
PDF WOBURN, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology will be used in a double-blinded, randomized, s [Read more]